Related Experiment Video

Updated: Jun 21, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

The influence of anemia after percutaneous coronary intervention on clinical outcomes

Sudhakar Sattur1, Kishore J Harjai, Arvin Narula

  • 1Department of Internal Medicine, University of Arizona, Tucson, Arizona, USA.

Clinical Cardiology
|July 18, 2009
PubMed

Insights

Post-PCI anemia (PPA) is common after cardiac procedures and is linked to worse patient outcomes. This anemia often occurs without significant bleeding, highlighting its independent prognostic importance.

Area of Science:

  • Cardiology
  • Hematology
  • Interventional Cardiology

Background:

  • Bleeding after percutaneous coronary intervention (PCI) is known, but the clinical impact of post-PCI anemia (PPA) remains unstudied.
  • PPA is defined as a post-PCI hemoglobin level below 10 gm/dL.

Purpose of the Study:

  • To investigate the incidence, predictors, and prognostic significance of PPA on clinical outcomes in patients undergoing PCI.
  • To compare outcomes between patients with and without PPA.

Main Methods:

  • A cohort of 1415 PCI procedures was analyzed.
  • Patients were categorized based on the presence or absence of PPA (nadir hemoglobin < 10 gm/dL).
  • Outcomes were assessed, including the influence of bleeding events, hemoglobin drop, and blood transfusions in patients with PPA.

Main Results:

  • Post-PCI anemia (PPA) occurred in 8.8% of patients.
  • Patients with PPA had significantly higher rates of 6-month mortality (6.5% vs. 1.7%), 6-month major adverse cardiovascular events (MACE) (27.3% vs. 14.5%), and long-term mortality (25.8% vs. 8.7%).
  • PPA independently predicted worse outcomes, even in the absence of significant bleeding or hemoglobin drop.

Conclusions:

  • Post-PCI anemia is a frequent complication following cardiac procedures.
  • PPA is associated with significantly poorer clinical outcomes, including increased mortality and MACE.
  • The prognostic impact of PPA is evident irrespective of bleeding events or the magnitude of hemoglobin decrease.
Abstract

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...